Gold complex QB1561 suppresses drug-resistant cancer cells by inhibiting TrxR and mitochondrial respiratory function
Hai-Ling Gao1, Wenwen Ding2, Zhi-Xin Shen3
1Department of Histology and Embryology, Shandong Second Medical University, Weifang, Shandong, China.
Introduction:
Multi-drug resistance (MDR) is one of the leading reasons that cause the failures of cancer treatment. Novel agents that may reverse MDR and neutralize drug-resistant cancer cells are highly desirable for clinical practice. The targeting of cellular redox homeostasis and/or mitochondria-mediated energy metabolism are promising strategies for the suppression of drug-resistant cancer cells. Based on the structure of mono-gold(I) complex auranofin (AF), a drug candidate under clinical trials for cancer, we synthesized a new dual-gold(I) complex QB1561 and tested if it can inhibit drug-resistant cancer cells overexpressing ATP-binding cassette (ABC) transporters. We also investigated if QB1561 could inhibit thioredoxin reductase (TrxR), a well-known target of AF and other gold complexes, and assessed its impact on mitochondrial respiration.
Methodology:
Cell viability of drug-resistant cells upon QB1561 alone or combined with topotecan and mitoxantrone was determined by MTS assay. The expression of ABC sub-family G member 2 (ABCG2) in the lung cancer cell line NCI-H460/MX20 after treatment with QB1561 was assessed by Western blot. The Vi-sensitive ABCG2 ATPase activity in the membrane vesicles of High Five insect cells, TrxR activity, and ROS production were measured following QB1561 treatment. Colony formation was used to assess QB1561's anticancer potential. SeaHorce Seahorse XF Analyzers were used to measure the oxygen consumption rate (OCR).
Results:
QB1561 suppressed the proliferation of drug-resistant cancer cells overexpressing ABC transporters, with IC50 values ranging from 0.57 to 1.80 μM, which was more effective than AF. QB1561 was able to partially reverse the resistance of mitoxantrone and topotecan in lung cancer NCI-H460/MX20 cells which overexpressed ABCG2, without altering the expression levels of ABCG2. QB1561 suppressed the colony formation of NCI-H460/MX20 cells, probably via ROS induction due to TrxR inhibition. QB1561 also efficiently suppressed OCR, suggesting its inhibition on mitochondrial respiration.
Conclusion:
QB1561 was effective for the treatment of MDR in drug-resistant cancer cells. Its further evaluation could be useful for the design and development of more gold-based anticancer drugs.
Insights
A new dual-gold(I) complex, QB1561, effectively inhibits drug-resistant cancer cells by targeting ATP-binding cassette transporters and thioredoxin reductase. This novel agent shows promise for overcoming multi-drug resistance (MDR) in cancer therapy.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- Multi-drug resistance (MDR) significantly limits cancer treatment efficacy.
- Targeting cellular redox homeostasis and mitochondrial metabolism are key strategies against drug-resistant cancers.
- Auranofin (AF), a gold(I) complex, is a clinical candidate for cancer treatment.
Purpose of the Study:
- To synthesize and evaluate a novel dual-gold(I) complex, QB1561, for its efficacy against drug-resistant cancer cells.
- To investigate QB1561's mechanism of action, including its effects on ATP-binding cassette (ABC) transporters, thioredoxin reductase (TrxR), and mitochondrial respiration.
Main Methods:
- Cell viability assays (MTS) and colony formation assays were used to assess QB1561's anticancer potential.
- Western blot analysis determined ABCG2 expression levels.
- Enzyme activity assays measured TrxR activity and ABCG2 ATPase activity.
- Seahorse XF Analyzers measured oxygen consumption rate (OCR) to assess mitochondrial respiration.
Main Results:
- QB1561 demonstrated superior efficacy compared to AF in suppressing drug-resistant cancer cell proliferation (IC50 values 0.57–1.80 μM).
- QB1561 partially reversed resistance to mitoxantrone and topotecan in ABCG2-overexpressing lung cancer cells without altering ABCG2 expression.
- QB1561 inhibited TrxR, induced ROS production, suppressed colony formation, and inhibited mitochondrial respiration (OCR).
Conclusions:
- QB1561 is a potent agent effective against multi-drug resistant cancer cells.
- QB1561's mechanisms involve TrxR inhibition, ROS induction, and suppression of mitochondrial respiration.
- Further evaluation of QB1561 could guide the development of novel gold-based anticancer drugs.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
11:13Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers